A Pilot Study of Fenofibrate to Prevent Kidney Function Loss in Type 1 Diabetes


The purpose of this study is to learn more about the effect of a drug called fenofibrate on kidney function in people with type 1 diabetes. A few studies have suggested that fenofibrate may slow loss of kidney function in people with type 2 diabetes. However, it has not been given to people specifically with type 1 diabetes mellitus to reduce their chances to develop kidney disease. The information gathered in the present study will be used to design a larger study to see whether fenofibrate can be used to prevent kidney function loss also in people with type1 diabetes.

This study involves:

  • 8 study visits over 1 ½ years
  • Take 1 fenofibrate pill or inactive pill daily
  • Comprehensive kidney function exams at 4 of the study visits
  • Blood and urine tests
  • EKG

All study related procedures are provided at no charge.
Monetary compensation and parking validation will be provided for eligible study participants.


  • Age 18-70
  • Diagnosed with type 1 diabetes
  • Have had diabetes for at least 8 years
  • We determine that you have signs of kidney problems due to diabetes


The PERL-Fenofibrate Study<
> Email: PERL-Fenofibrate [at] joslin.harvard.edutarget="_blank" title="Email the PERL-Fenofibrate Study"
Toll free: 1-866-622-3885